glp-1 obesity drugs pipeline GLP Agonist Clinical Trial Appears Robust With 20+ glp-1 obesity drugs pipeline New
Description
95% CI 141.16, 79.6)
A recent analysis of FDA adverse event reporting system (FAERS) data from 2004 to 2020 revealed a notable association between GLP-1 RAs and malignant pancreatic neoplasms (proportional reporting ratio [PRR], 9.86) [52]
Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V
TorHorman Law is awesome I cant say enough how grateful I was to have TorHoerman Law help with my case
Li, H.-Y
